Auron Therapeutics

Focus: Auron Therapeutics is an early-stage oncology-focused biotech founded in 2024, pioneering differentiation therapy approaches for hematologic and solid tumors. The company is publicly traded but appears to be in very early clinical development with minimal commercial infrastructure.

Oncology Unknown

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Auron Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Auron Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

2 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

AUTX-703

Relapsed/Refractory Acute Myeloid Leukemia

Phase 1

Clinical Trials (1)

NCT06846606Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS

Phase 1

Help build intelligence for Auron Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Ground-floor opportunity at a publicly traded company with a novel differentiation therapy platform in oncology
Pipeline includes Phase 2/3 program (AMT2003) in hepatocellular carcinoma, offering potential near-term clinical catalysts
Rare chance to shape company culture and processes during critical growth phase post-IPO

Watch Out For

Extreme early-stage risk: only 1 active job posting and minimal disclosed employee base suggests company is still assembling core team
No revenue, financial data, or disclosed funding—sustainability and capital runway are undisclosed critical unknowns

Generated by Claude from Auron Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

AMT2003

Hepatocellular Carcinoma

Phase 2/3

Clinical Trials (3)

NCT00332280Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo

Phase 2/3

NCT00405561Study to Evaluate Progression Free Survival in Cancer Patients With Advanced Colorectal Carcinoma With AMT2003

Phase 2/3

NCT00405873Study to Evaluate Tumour Response in Cancer Patients With Advanced Hepatocellular Carcinoma (Liver Cancer) With AMT2003

Phase 2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2024

Portfolio: 4 clinical trials

Top TAs: Oncology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

4 pipeline

Marketed

Pipeline